{
  "id": 6276780,
  "title": "Guggenheim raises Merck stock price target to $170 on cancer drug",
  "url": "https://urgent.news/2026/09/08/guggenheim-raises-merck-stock-price-target-to-170-on-cancer-drug",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-08T12:09:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/guggenheim-raises-merck-stock-price-target-to-170-on-cancer-drug-93CH-4891575"
  },
  "original_language": "en",
  "account": "Guggenheim upgraded its price target for Merck & Co. (MRK) shares to $170 from $146, maintaining a Buy rating. The firm increased its sales estimates for intismeran autogene, the drug co-developed by Merck and Moderna Inc. (MRNA), following positive topline data from the two companies. Guggenheim's market model suggests around $7 billion in probability-adjusted sales potential by 2035, with profits split equally between the two companies. The firm expects data from the INTerpath-001 trial at the European Society of Medical Oncology Meeting in October. Merck's stock surged 11.2% since the intismeran topline news, outperforming the S&P 500's 0.4% increase. Guggenheim also highlighted the potential for sacituzumab tirumotecan, estimating it could generate $7 billion in sales by 2035. The firm anticipates Merck will face steep decline amid competition from intravenous biosimilars of Keytruda as it navigates through this period.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}